The Effect of Fatigue on Lower Extremity Electromyography During Clean Performance in Elite Female Weightlifters

The clean is a primary movement in the sport of Olympic weightlifting. Management of fatigue is essential to optimizing weightlifting performance. The purpose of this study was to examine the effects of fatigue on EMG activation during clean performance in elite female weightlifters. Electromyography (EMG) data was collected bilaterally from the vastus lateralis (VM) and vastus lateralis (VL) during maximum voluntary isometric contraction (MVIC) and clean trials. Muscle activity was collected during pre- and post-fatigue clean trials at 60%, 70%, and 80% of the subject’s self-reported one repetition maximum (1RM). Subjects completed a fatiguing protocol consisting of two sets of front squats until failure at 80% 1RM. The results showed a significant decrease in EMG activation between 70% and 80% 1RM for the left VL. We found no significant differences between pre- and post-fatigue EMG activity across the measured muscles. This study provides information regarding the fatigue resistance of elite female weightlifters

Erma Bombeck Writing Competition: Humor Local Honorable Mention- Hamburger helper cheesy taco casserole

After the oven fire -- French\u27s French Fried Onions ignite in the broiler -- and the explosion -- never heat Prego in a glass bowl on a burner -- I should have invested in culinary school, meal delivery, or a stomach pump. Instead I kept on

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety

<p>Background: Melatonin is extensively used in the USA in a non-regulated manner for sleep disorders. Prolonged release melatonin (PRM) is licensed in Europe and other countries for the short term treatment of primary insomnia in patients aged 55 years and over. However, a clear definition of the target patient population and well-controlled studies of long-term efficacy and safety are lacking. It is known that melatonin production declines with age. Some young insomnia patients also may have low melatonin levels. The study investigated whether older age or low melatonin excretion is a better predictor of response to PRM, whether the efficacy observed in short-term studies is sustained during continued treatment and the long term safety of such treatment.</p> <p>Methods: Adult outpatients (791, aged 18-80 years) with primary insomnia, were treated with placebo (2 weeks) and then randomized, double-blind to 3 weeks with PRM or placebo nightly. PRM patients continued whereas placebo completers were re-randomized 1:1 to PRM or placebo for 26 weeks with 2 weeks of single-blind placebo run-out. Main outcome measures were sleep latency derived from a sleep diary, Pittsburgh Sleep Quality Index (PSQI), Quality of Life (World Health Organzaton-5) Clinical Global Impression of Improvement (CGI-I) and adverse effects and vital signs recorded at each visit.</p> <p>Results: On the primary efficacy variable, sleep latency, the effects of PRM (3 weeks) in patients with low endogenous melatonin (6-sulphatoxymelatonin [6-SMT] ≤8 μg/night) regardless of age did not differ from the placebo, whereas PRM significantly reduced sleep latency compared to the placebo in elderly patients regardless of melatonin levels (-19.1 versus -1.7 min; P = 0.002). The effects on sleep latency and additional sleep and daytime parameters that improved with PRM were maintained or enhanced over the 6-month period with no signs of tolerance. Most adverse events were mild in severity with no clinically relevant differences between PRM and placebo for any safety outcome.</p> <p>Conclusions: The results demonstrate short- and long-term efficacy and safety of PRM in elderly insomnia patients. Low melatonin production regardless of age is not useful in predicting responses to melatonin therapy in insomnia. The age cut-off for response warrants further investigation.</p&gt

Parasomnias and Antidepressant Therapy: A Review of the Literature

There exists a varying level of evidence linking the use of antidepressant medication to the parasomnias, ranging from larger, more comprehensive studies in the area of REM sleep behavior disorder to primarily case reports in the NREM parasomnias. As such, practice guidelines are lacking regarding specific direction to the clinician who may be faced with a patient who has developed a parasomnia that appears to be temporally related to use of an antidepressant. In general, knowledge of the mechanisms of action of the medications, particularly with regard to the impact on sleep architecture, can provide some guidance. There is a potential for selective serotonin reuptake inhibitors, tricyclic antidepressants, and serotonin–norepinephrine reuptake inhibitors to suppress REM, as well as the anticholinergic properties of the individual drugs to further disturb normal sleep architecture

A System for Retrieving Statistics of Citations for Publications of Groups of Authors

Existuje několik organizací, které uchovávají data o vědeckých publikacích, jejich autorech a citacích, ale informační systémy těchto organizací neumožňují zobrazit statistiky pro skupiny autorů. Mým úkolem bylo navrhnout a vyvinout systém, který získá informace o citacích autorů naší univerzity z databází organizací Scopus a Web of Science. Výsledný systém měl data zpracovat, uložit a přehledně zobrazit statistiky citačního ohlasu jednotlivých autorů v informačním systému dle předem definovaných skupin včetně souhrnných statistik pro celé skupiny odpovídající rozdělení univerzity jako jsou fakulty nebo katedry. Proto byl vytvořen informační systém s přístupovými objekty, které přistupují k API citačních databází. Informační systém následně získané informace ukládá do vlastní databáze a přepočítává H-indexy autorů. Systém zobrazuje výsledné informace v uživatelském rozhraní a umožňuje základní úpravné operace nad skupinami, autory i jejich pracovními zařazeními. Skupiny je možné vytvořit a upravit v hierarchii odpovídající členění univerzity. Informace o citačním ohlasu jsou získávány a zpracovávány v pravidelných intervalech.Some organizations manage data of scientific articles their authors and citations, but the information systems of these organizations do not show statistics for the groups of authors. My task was to design and develop a system which obtains citations information from databases of organizations Scopus and Web of Science. Only citations of authors of our university should be obtained. The resulting system should process the data, stores them and display citations statistics of individual authors clearly in information system according to predefined groups. System should display summary statistics for the whole groups too. Groups are corresponding to division of the university such as faculties or departments. So an information system with access objects was created that accesses the API of citation databases. Information system then subsequently stores data in its own database and calculates H-Indexes of authors. System displays the resulting information in the user interface and also allows basic editing operations with groups, authors and their job titles. Groups can be created and edited in the hierarchy corresponding to the subdivision of the university. Information of citations are collected and processed at regular intervals.460 - Katedra informatikyvelmi dobř

Individual Professional Practice in the Company

Import 05/08/2014Smyslem této práce je ukázat využití mých teoretických znalostí, nabytých ze školy, v praxi na konkrétních úkolech. Hlavním úkolem bylo vytvoření webové aplikace DataBroker Emulator, která slouží k testování nově vyvíjených, či přepracovaných aplikací, které budou z aplikace DataBroker získávat data, a ty budou dále aplikacemi zpracovávána. Druhým úkolem bylo vyvinout desktopovou aplikaci nazvanou DataBroker TestClient, kterou bude možné testovat DataBroker Emulator a samotný DataBroker. Posledním úkolem, na kterém jsem v rámci odborné praxe pracoval, byla aplikace ComplexityMatrixTool, která má za úkol vypočítat rizika projektů v těžařství.The purpose of this work is to demonstrate the use of my theoretical knowledge acquired in school in practice on specific tasks. The main task was to create a web application DataBroker Emulator, which is used to test newly developed or overworked applications, that obtain data from DataBroker application and this data will be processed by these applications. The second task was to develop a desktop application called DataBroker TestClient which can be tested DataBroker Emulator and DataBroker to. The final task on which I worked during the professional practice was ComplexityMatrixTool application, whose task is to calculate the risk in mining projects.460 - Katedra informatikyvýborn

Parenting skills manual for clients in recovery treatment for chemical dependency

The Parenting Skills Manual provides a format to aid counselors in presenting a Parenting Skills Program for clients in recovery to enhance the acquisition of knowledge and skills for positive parenting as well as dealing with reparenting to advance a client's own developmental process and possibly promote understanding of, caring for, and relating to their own children. These children are at a higher risk for substance abuse (Kaufman, 1989) and parenting education may be considered as one link in the chain of prevention. The concepts acquired in the Parenting Sessions can be used regardless of whether we are relating to children, our own self, or others. Effective communication, expressing feelings, coping with stress, developing self-worth, self-discipline and mutual respect are fundamental in forming good relationships. One can shift the focus over from learning how to parent our children to reparenting ourselves and relating to others. Clients in recovery are changing and building a new life. Parenting is a vital part of this process and an aid to finding "the good parent within" as the client becomes self-reliant and copes with life without substance abuse. The research of the literature in Chapter 2 provides an exploration of chemical dependency and parenting programs and serves as an orientation to the program presented in the manual. This manual is a guide for the counselor to create a safe, supportive atmosphere where learning can take place along with the therapy in learning. The manual aims for a participatory (experiential) approach, incorporated within the presentation of concepts, to promote self-discovery and personal meaning.California State University, Northridge. Department of Psychology.Includes bibliographical references (pages 171-175

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a respiratory disease that causes progressive symptoms of breathlessness, cough and mucus build-up. It is the fourth or fifth most common cause of death worldwide and is associated with significant healthcare costs.Inhaled long-acting beta2-agonists (LABAs) are widely prescribed to manage the symptoms of COPD when short-acting agents alone are no longer sufficient. Twice-daily treatment with an inhaled LABA is aimed at relieving symptoms, improving exercise tolerance and quality of life, slowing decline and even improving lung function and preventing and treating exacerbations. OBJECTIVES: To assess the effects of twice-daily long-acting beta2-agonists compared with placebo for patients with COPD on the basis of clinically important endpoints, primarily quality of life and COPD exacerbations. SEARCH METHODS: We searched the Cochrane Airways Group trials register, ClinicalTrials.gov and manufacturers' websites in June 2013. SELECTION CRITERIA: Parallel, randomised controlled trials (RCTs) recruiting populations of patients with chronic obstructive pulmonary disease. Studies were required to be at least 12 weeks in duration and designed to assess the safety and efficacy of a long-acting beta2-agonist against placebo. DATA COLLECTION AND ANALYSIS: Data and characteristics were extracted independently by two review authors, and each study was assessed for potential sources of bias. Data for all outcomes were pooled and subgrouped by LABA agent (formoterol 12 μg, formoterol 24 μg and salmeterol 50 μg) and then were separately analysed by LABA agent and subgrouped by trial duration. Sensitivity analyses were conducted for the proportion of participants taking inhaled corticosteroids and for studies with high or uneven rates of attrition. MAIN RESULTS: Twenty-six RCTs met the inclusion criteria, randomly assigning 14,939 people with COPD to receive twice-daily LABA or placebo. Study duration ranged from three months to three years; the median duration was six months. Participants were more often male with moderate to severe symptoms at randomisation; mean forced expiratory volume in 1 second (FEV1) was between 33% and 55% predicted normal in the studies, and mean St George's Respiratory Questionnaire score (SGRQ) ranged from 44 to 55 when reported.Moderate-quality evidence showed that LABA treatment improved quality of life on the SGRQ (mean difference (MD) -2.32, 95% confidence interval (CI) -3.09 to -1.54; I(2) = 50%; 17 trials including 11,397 people) and reduced the number of exacerbations requiring hospitalisation (odds ratio (OR) 0.73, 95% CI 0.56 to 0.95; I(2) = 10%; seven trials including 3804 people). In absolute terms, 18 fewer people per 1000 were hospitalised as the result of an exacerbation while receiving LABA therapy over a weighted mean of 7 months (95% CI 3 to 31 fewer). Scores were also improved on the Chronic Respiratory Disease Questionnaire (CRQ), and more people receiving LABA treatment showed clinically important improvement of at least four points on the SGRQ.The number of people who had exacerbations requiring a course of oral steroids or antibiotics was also lower among those taking LABA (52 fewer per 1000 treated over 8 months; 95% CI 24 to 78 fewer, moderate quality evidence).Mortality was low, and combined findings of all studies showed that LABA therapy did not significantly affect mortality (OR 0.90, 95% CI 0.75 to 1.08; I(2) = 21%; 23 trials including 14,079 people, moderate quality evidence). LABA therapy did not affect the rate of serious adverse events (OR 0.97, 95% CI 0.83 to 1.14; I(2) = 34%, moderate quality evidence), although there was significant unexplained heterogeneity, especially between the two formoterol doses.LABA therapy improved predose FEV1 by 73 mL more than placebo (95% CI 48 to 98; I(2) = 71%, low quality evidence), and people were more likely to withdraw from placebo than from LABA therapy (OR 0.74, 95% CI 0.69 to 0.80; I(2) = 0%). Higher rates of withdrawal in the placebo arm may reduce our confidence in some results, but the disparity is more likely to reduce the magnitude of difference between LABA and placebo than inflate the true effect; removing studies at highest risk of bias on the basis of high and unbalanced attrition did not change conclusions for the primary outcomes. AUTHORS' CONCLUSIONS: Moderate-quality evidence from 26 studies showed that inhaled long-acting beta2-agonists are effective over the medium and long term for patients with moderate to severe COPD. Their use is associated with improved quality of life and reduced exacerbations, including those requiring hospitalisation. Overall, findings showed that inhaled LABAs did not significantly reduce mortality or serious adverse events